ArticleWorld journal of orthopedics2023
Osteoarthritis, an old wine in a new bottle!
Article in World journal of orthopedics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials.Arthritis research & therapy · 2026Article
- Towards stratification in osteoarthritis: a review of the scientific terminology used in published basic research.BMC rheumatology · 2025Review
- Comparative outcome analyses of stromal vascular fractionWorld journal of experimental medicine · 2025Article
- Subchondral Cellular Density Decreases with Increasing Grade of Cartilage Degeneration in Knee Osteoarthritis - An Ex vivo Histopathological Analysis.Journal of orthopaedic case reports · 2025Article
- Obese Patients Do Not Benefit from Bone Marrow Aspiration Concentrate Injection for Knee Osteoarthritis: A Prospective Cohort Study of 68 Patients.Indian journal of orthopaedics · 2025Article
- Effect of Cellular Dosage of Bone Marrow Aspiration Concentrate on the Radiological Outcomes in Knee Osteoarthritis: A Phase I Dose-Escalation Study.Indian journal of orthopaedics · 2024Article
- Increased Cellular Dosage of Bone Marrow Aspiration Concentrate Does Not Translate to Increased Clinical Effectiveness in Knee Osteoarthritis: A Phase I Dose Escalation Study.Indian journal of orthopaedics · 2024Article
- Beginning of the era of Organ-on-Chip models in osteoarthritis research.Journal of clinical orthopaedics and trauma · 2024Article
- Does progress in microfracture techniques necessarily translate into clinical effectiveness?World journal of orthopedics · 2024Article
- Enhancement of the therapeutic efficacy of mesenchymal stem cell-derived exosomes in osteoarthritis.Cellular & molecular biology letters · 2023Review
- Factors Influencing the Yield of Progenitor Cells in Bone Marrow Aspiration Concentrate-A Retrospective Analysis of 58 Patients.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is the most common form of arthritis that has a major impact on patient morbidity and health care services. Despite its prevalence and impact, we do not have any effective management strategy to prevent or control their manifestations. Several decades of pharmacological development have failed to deliver a disease-modifying solution to OA. This editorial article outlines the lacunae in the research efforts of the past, the challenges that we are facing at present, and the exciting opportunities we have in the future for the management of OA. OA research has to be made more personalized concerning the phenotypic and endotypic disease variants. To begin with, robust disease classification criteria need to be defined for early OA, and biomarkers to detect such early diseases to aid in patient stratification. We also need to refine our clinical research design to make them more objective to meet the demands of the patient and the regulatory agencies. Embracing the current technologies such as artificial intelligence along with the use of genomic profiling from the omics platforms, the future of OA is more promising in developing appropriate management of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.